Akeso's Ligufalimab Secures FDA Orphan Drug Designation for AML Treatment Akeso's novel IgG4 monoclonal antibody, ligufalimab, has received FDA Orphan Drug Designation for acute myeloid leukemia, aiming to provide better treatment options.

Akeso's Ligufalimab Secures FDA Orphan Drug Designation for AML Treatment #AML #Akeso #Ligufalimab